Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 2025 Annual Report: Key Investor Insights

1. Overview & Strategic Highlights

• IPO Milestone: Hanx Biopharmaceuticals successfully listed its H Shares on the Main Board of the Hong Kong Stock Exchange on December 23, 2025, raising net proceeds of approximately HKD 531.3 million. As of the end of the reporting period, none of these proceeds had been utilized, with the company targeting full deployment by 2030. The funds are allocated as follows: 35% for core product HX009 R&D, 33% for key products HX301 and HX044, 17% for other pipeline candidates, 5% for commercialization/business development, and 10% for working capital and general corporate purposes.
• R&D Investment & Platform Strengthening: The company continues to heavily invest in its core technology platforms, VersatiBody™ and autoRx40™, aiming to maintain a technological edge in antibody drug development and to solidify its long-term competitiveness.
• Product Commercialization Push: Hanx is advancing pivotal clinical trials, especially for its lead candidate HX009. It is exploring both out-licensing of assets and direct commercialization to generate a stable operating cash flow.
• Global Expansion: The company is actively pursuing product registration and commercialization in major markets such as the US, EU, and Australia, and seeking strategic collaborations and licensing opportunities.

2. Financial Performance & Key Metrics

• Other Income and Gains: The company reported a 115.6% year-on-year increase in other income and gains, reaching RMB 16.6 million (2024: RMB 7.7 million). The surge was primarily due to a significant fair value gain (RMB 13.98 million) on contingent consideration related to the disposal of an associate.
• Liquidity Position: Cash and cash equivalents soared to RMB 614.4 million, a 281% increase from RMB 161.2 million at the end of 2024. This reflects strong fundraising and a robust liquidity position post-IPO.
• Gearing Ratio: A dramatic shift in the balance sheet, with the gearing ratio dropping from 56.8% to 20.0% due to increased equity capital and reduced liabilities following the IPO.
• Loss for the Year: Net loss widened to RMB 131.5 million (2024: RMB 116.9 million), reflecting increased R&D, administrative, listing, and finance costs. Administrative expenses rose to RMB 44.4 million (+25.2%), listing expenses to RMB 13.7 million (+27.4%), and finance costs to RMB 11.6 million (+23.4%). The company attributes these increases to expansion and IPO-related activities, with redemption liabilities ceasing to accrue interest post-listing.

3. Business & Operational Risks

• Market Competition: Hanx faces fierce competition, especially for its core HX009 product. The risk exists that competitors may develop more advanced or effective therapies, potentially impacting commercial prospects.
• Clinical and Regulatory Risks: Adverse events or side effects in clinical trials, particularly with CD47-targeted molecules, could delay or derail approvals and commercialization.
• Commercialization Risk: The company’s future hinges on successful clinical development and commercialization of its pipeline. Any setbacks could materially impact its financial position and valuation.

4. Corporate Governance & Shareholder Matters

• Governance Standards: The board asserts full compliance with the Corporate Governance Code since listing. The roles of Chairman and CEO are separated for balance of power. Directors receive continuous training and induction.
• Shareholder Communication: Multiple channels are in place, including annual general meetings, webcasts, and a dedicated investor relations contact. The company has a Shareholders Communication Policy and will conduct annual reviews of its effectiveness.
• Dividend Policy: No dividend was declared for 2025, and the company has no formal dividend payout policy. Future dividends will depend on financial conditions and board recommendation.
• Share Capital & Incentive Plans: The company undertook a share split and IPO in 2025. It maintains a stock option and restricted share incentive plan for employees, with no further grants post-listing.

5. Related Party Transactions, Legal & Compliance

• Suppliers: No commercialized products or customers in 2025. Purchases from the top five suppliers accounted for 41.6% of total purchases, with all major suppliers being independent third parties.
• Legal Proceedings: The group was not involved in any material legal proceedings during the reporting period.
• Connected Transactions: All non-exempt continuing connected transactions were confirmed by independent non-executive directors and auditors to be fair, reasonable, in the ordinary course of business, and compliant with the Listing Rules.
• Financial Assistance: No loans or guarantees were provided to directors, supervisors, senior management, controlling shareholders, or their associates.

6. Price-Sensitive & Shareholder-Relevant Information

• IPO and Use of Proceeds: The successful IPO and strong liquidity position are positive for future development and may support share price. However, the lack of product commercialization and ongoing net losses may temper short-term optimism.
• Intensified R&D and Global Expansion: Aggressive investment in R&D and entry into global markets could drive future growth but also add to near-term operational losses.
• Risk of Delays: Any setbacks in clinical trials or regulatory approvals for core products would be highly price sensitive and could negatively affect share value.
• No Dividend: The absence of a dividend policy and current losses may be a concern for income-focused investors.
• Redemption Liabilities Terminated: The cessation of interest accrual on redemption liabilities post-IPO improves the company’s financial outlook.

7. Conclusion

Hanx Biopharmaceuticals has achieved a significant milestone with its IPO, securing substantial funds for its ambitious R&D and global commercialization plans. The company is well-capitalized, and its strategic focus on innovation platforms and lead asset development positions it for long-term growth. However, investors should be mindful of continued operating losses, heavy R&D spending, lack of commercial revenues, and the inherent risks associated with clinical-stage biopharmaceutical firms. Any material news from clinical trials, regulatory milestones, or partnership/licensing deals could move the share price significantly in the coming periods.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should conduct their own research and consult with their professional advisers before making any investment decisions. The information is based on the 2025 Annual Report of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. and is subject to change without notice.

View HANXBIO-B Historical chart here